NCT06840899PHASE2Recruiting

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

University of Wisconsin, Madison

Start Date

2/13/2026

Completion Date

5/1/2027

Summary

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days

Detailed Description

This pilot study assesses the feasibility of using 100mg of twice daily cannabidiol (Epidiolex) in adult spinal cord injury with neurogenic lower urinary tract dysfunction following resolution of spinal shock.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * \>18 years of age * History of supra-sacral spinal cord injury of any mechanism * Urinary incontinence with ≥2 episodes of urinary incontinence per day (outside of spinal shock) * Willingness to participate in drug intervention trial * English-speaking (able to provide consent and complete questionnaires) Exclusion Criteria: * History of intravesical Botox * Actively taking \>15 mg of Oxybutynin single dose or equivalent dose of alternative anticholinergic medication for bladder symptoms * Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported * Thought or mood disorder aside from depression

Interventions

DRUG

CBD

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Supra-sacral Spinal Cord InjurySpinal Cord InjuryUrinary Incontinence

Locations

University of Wisconsin - Madison

Madison, Wisconsin 53705

United States